key: cord-0867105-ybbwqgxg authors: Dooley, Michael title: Strengthening what we already have: collaborations to prevent medication shortages amid COVID‐19 date: 2020-07-04 journal: Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia DOI: 10.1002/jppr.1670 sha: 55fd9e30444785bf98dcb03e434ff74a2f01b3cf doc_id: 867105 cord_uid: ybbwqgxg nan In recent months we have all experienced the many challenges presented by the COVID-19 pandemic. It was only at the end of 2019 that this novel coronavirus emerged, and for most of us the potential implications didn't hit home until February this year or even later. 1 Since this time, we have had to make many decisions, both professionally and personally. We have had to balance the many risks associated with COVID-19 against the benefits of activities and services that could increase exposure and the consequences of infection. This has been challenging, especially as the evidence to guide such decision-making has been rapidly evolving. The haste to provide evidence to support practice has created additional challenges, with the rigor of analysis sometimes being compromisedthe case of hydroxychloroquine is a very recent example. 2 Ultimately, the pandemic has required us to be more open in our thinking. We have needed to harness the creativity that exists to identify the many problems ahead, and the solutions to these problems. Globally there has been, and continues to be, massive demands on health system capacity, resulting in rationing of resources as demand has outstripped supply. 3 There have been significant efforts to increase capacity, with immediate recognition of the lack of ventilators and personal protective equipment (PPE). Medication shortages were becoming apparent in countries with large numbers of COVID-19 patients. These shortages were a result of both 'required demand', that is for specific use to provide care, and for 'perceived demand', such as community stockpiling. In Australia, the early attention was on shortages within the ambulatory sector associated with potential stockpiling by concerned individuals, a phenomenon experienced elsewhere. 4 However, the major risk was the potential for shortages of critical medications for ventilated patients. This was soon recognised by clinicians, especially those within critical care and pharmacy, and within the pharmaceutical supply chain. Concerns regarding shortages of intravenous opioid analgesics, sedatives and neuromuscular blocking agents (NMB) were raised from February onwards and reflected experiences in countries with significant cases of COVID-19. 5 The challenges faced locally and nationally in addressing the potential shortages of these critical medicines were significant. The clinical course of the disease was largely unknown and the evidence to guide practice was scant. Modelling was performed that projected potential requirements for intensive care admissions and capacity. 6, 7 Health services everywhere were tasked with preparing for a massive influx of patients requiring ventilation. This required a parallel increase in the availability of these essential medications. Clinician preferences for NMB and sedation wasn't known. The dosages and duration required were unknown. The potential availability of these medications from the pharmaceutical supply chain was also unknown. What we did know was that we needed to act and act quickly. As always in a time of crisis, the existing foundations either provide strength to build upon, or weaknesses that soon become evident. During the last few months the collaborations that already existed within and beyond our health services, within and beyond our healthcare professions, and within and beyond our borders have been a foundation enabling so much to be achieved in a short time. There are numerous examples from this effort that we could all share, and I will illustrate this with just a few. Intensivists, anaesthetists and ICU pharmacists worked together to identify the national preferences for medications for ventilated patients. A national survey of clinicans was developed, undertaken and completed within only two weeks. The results were instrumental in informing strategies and priorities to address medication availability for these patients. Multiple professional organisationsincluding the Society of Hospital Pharmacists of Australia (SHPA), the Australian and New Zealand Intensive Care Society (ANZICS), and the Australian and New Zealand College of Anaesthetists (ANZCA)worked to provide input and evidence to inform decisions regarding availability of these medications. Consensus guidelines for the clinical care of patients were developed through the National COVID-19 Clinical Evidence Taskforce that also built upon existing expertise and collaborations. 8 The availability of these critical medications was tracked through weekly hospital pharmacy snapshot surveys conducted by SHPA. The Commonwealth Department of Health, through the Medicine Shortages Taskforce of the Therapeutic Goods Administration, facilitated engagement with the key supply chain stakeholders, including Medicines Australia, the National Pharmaceutical Services Association (NPSA) and the Generic and Biosimilar Medicines Association (GBMA) amongst others. Data on medication availability was made available by the pharmaceutical companies. Data on usage in private hospitals was made available from private hospital providers. All our States and Territories were instrumental in providing medication usage data on all ventilated COVID-19 patients. This facilitated the development of a national demand model for these critical medicationspivotal to informing efforts to facilitate access to these medicines. This work is only one example of many in which the existing collaborations, expertise and dedicationof and between both individuals and institutions across this countryhas made an impact on the response to the pandemic. There are no doubt many things we could be doing better. There are more lessons still to be learnt, as there always is. 9,10 As we continue to work together through this pandemic, we will continue to benefit from the collaborations that we all haveand which we have strengthenedduring this time. Optimising the management of medications during the current COVID-19 pandemic has become a priority, both in ensuring the protection of staff who are administering drugs from contracting the virus, and in ensuring the appropriate use of medicines that may have, or could be at risk of, limited supply. Here we discuss how to deprescribe unnecessary medications and simplify medication management in the effort to reduce opportunities for transmission of COVID-19 between patients and staff. Streamlining medication regimens and their administration, as well as the associated drug-related monitoring of patients, may also increase the time that staff members have available for other direct care activities for both COVID and non-COVID patients. Guidance for medication optimisation and simplification in response to COVID-19 have recently been issued from Australian, 1 US 2 and international 3 sources. While our focus is on the care of patients in hospital with confirmed or suspected COVID-19 under infectious precautions, our recommendations can apply equally in the outpatient or 'virtual hospital' care, residential aged care, or primary care settings. In all cases, we include the disclaimer that the following statements are intended to be used to assist (not dictate) decision-making, and need to be consistent with the formulary, policies, procedures and guidelines of local drug and therapeutics committees. A novel coronavirus emerging in China -key questions for impact assessment Hydroxychloroquine or chloroquine with or without a macrolide for the treatment of COVID-10: a multinational registry analysis Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: data from community pharmacies. Res Social Adm Pharm 2020 Critical medication shortages further dwindling hospital resources during COVID-19 When a system breaks: a queuing theory model for the number of intensive care beds needed during the COVID-19 pandemic Surge capacity of intensive care units in case of acute increase in demand caused by COVID-19 in Australia Australian guidelines for clinical care of people with COVID-19. National COVID-19 Clinical Evidence Taskforce History in a crisis -lessons for Covid-19 Medication shortages during the COVID-19 crisis: what we must do